Vita Life Sciences Limited · ASX:VLS

Vita Life Sciences — H1 2022 Earnings Presentation

15 slides from Vita Life Sciences's earnings presentation, Aug 26, 2022

  1. Slide 1: Financial Results Half Year Ended 30 June 2022

    Financial Results Half Year Ended 30 June 2022

  2. Slide 2: Vita Life Sciences Ltd

    Vita Life Sciences Ltd Vita Life Sciences is an Australian owned healthcare company that is listed on the Australian Securities Exchange (ASX:VLS). Our core business is the development and Values Vita Life Sciences has a distribution of over the counter (OTC) medicines, as companywide commitment to:

  3. Slide 3: Commentary

    Commentary  Group sales of $32.7m, up 27% on prior corresponding period (PCP).  New customer acquisition and high consumer demand across key categories driving growth.  Domestic sales for both Australia and Malaysia combined with export GROUP SALES GROUP EBIT A$’m A$’m sales to China underpinned

  4. Slide 4: Australia

    Australia  Revenue of $18.5m an increase of 41% on PCP.  Domestic channel expansion combined with higher consumer offtake underpinned the performance. A$’m Revenue up 41% A$’m EBIT up 18%  New customer acquisition across the Pharmacy channel was 20 3 particularly strong.  Direct export revenue a

  5. Slide 5: Malaysia

    Malaysia  Revenue of $10.2m an increase of 19% on PCP.  Increased consumer demand domestically for both VitaHealth and Herbs of Gold brands underpinned the solid performance. A$’m  Additional ranging of the VitaHealth brand through modern trade Revenue up 19% A$’m EBIT up 39% 11 pharmacies suppor

  6. Slide 6: Singapore

    Singapore  Revenue of $2.8m a marginal increase on PCP.  Increased product ranging into “modern trade” retailers supported the improved performance. A$’m Revenue up 4% A$’m EBIT down 78% 0.6  The increase in product ranging across modern trade Pharmacies, 3 resulted in higher advertising and mark

  7. Slide 7: Other Asia

    Other Asia  Revenue of $1.3M a decrease of 9% on PCP  The Vietnam business started to show signs of normal trading conditions (post COVID).  Similar to the Group’s Thailand operations, Indonesian sales are now made through a third party distributor which reduced operating overheads whilst improvi

  8. Slide 8: Interim Dividend & Cashflows

    Interim Dividend & Cashflows  Operating cashflow conversion was impacted by the planned increase stock holding levels in order to service the significant increase in Group sales and the almost doubling of manufacturing lead times i.e. from Gross operating cashflow to EBITDA Interim dividend per sha

  9. Slide 9: Priorities & Outlook

    Priorities & Outlook  Domestic business across the Group’s key markets is expected to continue to be stable. New customer acquisitions and marketing initiatives and associated costs, in line with the 1st half, will continue for the remainder of the year.  New customer acquisition and marketing act

  10. Slide 10: Appendix

    Appendix VITA LIFE SCIENCES

  11. Slide 11: Half Year Results

    Half Year Results Half year ended June 2022 2021 $’m $’m Revenue 32.7 25.7 EBITDA 5.5 5.1 EBIT 5.3 4.9 Profit before tax 5.3 4.9 Profit after tax 3.6 3.7 EPS (Basic – cents/ share) 6.89 7.02 Dividend (cents / share) 2.75 2.75

  12. Slide 12: Balance Sheet

    Balance Sheet Balance Sheet as at Jun 2022 Dec 2021 $’m $’m Current assets 39.1 35.1 Non-current assets 10.4 10.2 Total assets 49.5 45.3 Current liabilities 15.3 14.5 Non-current liabilities 0.5 0.4 Total Liabilities 15.8 14.9 Net Assets 33.7 30.4

  13. Slide 13: Cash Flow

    Cash Flow Cash Flow for the half year ended June 2022 2021 $’m $’m Receipts from customers 32.5 27.4 Payments to suppliers and employees (30.8) (22.1) Gross operating cash flow 1.7 5.3 EBITDA 5.5 5.1 Gross operating cash flow / EBITDA 31% 103.9% Net interest (0.0) (0.0) Income tax paid (1.7) (1.0) O

  14. Slide 14: Andrew O'Keefe, Managing Director; Chin Lkhoo, CFO

    P a) / ANDREW O’KEEFE MANAGING DIRECTOR CHIN LKHOO CHIEF FINANCIAL OFFICER (e) +612 9545 2633 1/102 Bath Road, Kirrawee, NSW 2232 enquiries@vitalifesciences.com.au vitalifesciences.com VITA LIFE CIENCES

  15. Slide 15: Disclaimer

    Disclaimer This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences) and comprises written material/slides for a presentation concerning Vita Life Sciences. The presentation is for information purposes only and does not constitute or form part of any offer or invitation to a

Vita Life Sciences — H1 2022 Earnings Presentation on 6ix